Clinical Trial Update: A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating nerandomilast to slow progression in people with familial pulmonary fibrosis and related interstitial lung conditions is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Pulmonary Fibrosis
• Interstitial Lung Disease

Drugs mentioned

• Nerandomilast

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities | Phase 3 | Status: RECRUITING